The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 17, 2014

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Granulomatosis With PolyangiitisWegener GranulomatosisVasculitis
Interventions
DRUG

5 mg prednisone

Subjects will be randomized to take 5 mg per day of prednisone for a 6 month period.

DRUG

0 mg prednisone

Subjects will be randomized to taper their prednisone dose to no prednisone for a 6 month period.

Trial Locations (1)

33612

University of South Florida TAPIR Study Team, Tampa

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NIH

collaborator

Office of Rare Diseases (ORD)

NIH

collaborator

National Center for Advancing Translational Sciences (NCATS)

NIH

collaborator

Rare Diseases Clinical Research Network

NETWORK

lead

University of South Florida

OTHER